Fig. 3.

Most common any grade adverse events and ≥grade 3 events (per patient; worst grade anytime). Toxicity assessed as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, AE: Adverse event, Nal-IRI: Liposomal irinotecan.